Clinical Trial Search

Primary: Assessment of Early Response by 18F-Fluorodeoxyglucose(18F-FDG) Positron Emission Tomography/Computed Tomography (PET/CT) on Day 21 of Regorafenib Compared With the…

Primary: Number of Participants According to Year of Initial Diagnosis of Breast Cancer — 27; 28; 139; 1 Participants

Primary: Percentage of Participants Categorized Based on Treatment by Narcolepsy Type Since Diagnosis up to Study Visit — 5.10; 7.55; 94.90; 92.45 percentage of participants…

Primary: Number of Participants With a Superficial Incisional Surgical Site Infection (SSI) — 20; 27; 6; 9 Participants

Primary: Changes in Systolic Ambulatory Blood Pressure — -1.4; -2.9 mmHg — p=0.2682

Primary: Part 2: Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) — 15.3; 9.2 Months

Primary: Acceptability of the Intervention — 4.6 score on a scale

Primary: The Occurrence of Serious Adverse Events (SAE) Following Administration of G03-52-01 to the Final Follow-up Visit. — 0; 0; 0; 0 Number of SAEs

Primary: Achievement of Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Success at Week 4 — 28.9; 12.0 percentage of participants — p=<0.0001

Primary: Number of Participants With Adverse Events (AEs) — 8; 1 Participants

Primary: Patient Quality of Life (QOL) — 62.7; 54.4; 59.8; 51.9 score on a scale, range from 20 to 100 — p=>0.05

Primary: Overall 3D Movement — 1.46; 1.41 mm

Primary: Mean Amplitude of Duration of Auditory Mismatch Negativity (MMN) by Dose Level — -0.551; -0.749; -0.386; -1.084 microvolts

Primary: Mean Change in Subjective Well-being From Baseline to 6-week Follow-up on the Personal Well-Being Index - Intellectual Disability Version — 3.51; 3.59 units on a scale…

Primary: Depth of Hypnosis Adequacy — 79.4; 16.2 percentage of maintenance duration